Unicycive Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Research and Development (R&D) expense was $2.2 million for the quarter ended September 30, 2026, a decrease from $3.0 million in the same period in 2025, driven primarily by a $1.2 million reduction in development costs partially offset by a $0.5 million increase in non-cash stock-based compensation.
- General and Administrative (G&A) expense was $6.6 million for the quarter ended September 30, 2026, an increase from $4.4 million in the same period in 2025, driven by a $1.4 million increase in commercial launch preparation costs, a $0.6 million increase in non-cash stock-based compensation, and a $0.2 million increase in other labor costs.
- Other income (expense) was $1.8 million for the quarter ended September 30, 2026, compared to $1.3 million in income for the same period in 2025, primarily attributed to changes in the fair value of the company's warrant liability.
- Net loss attributable to common stockholders was $7.0 million, or $0.25 per share, for the quarter ended September 30, 2026, compared to a net loss of $6.0 million, or $0.33 per share, for the same period in 2025; the increased loss was primarily due to higher commercial launch expenses.
- Cash, cash equivalents, and marketable securities totaled $59 million as of September 30, 2026, with an expected runway extending beyond 2027, inclusive of anticipated expenses for a potential OLC launch.
Guidance and Future Outlook:
- The FDA accepted the New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC) with a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.
- The company plans to advance launch preparations in parallel with the FDA review to support a potential launch upon approval.
- The company expects to hire an optimized sales force in the first quarter of 2027 if OLC is approved by the FDA.
- The company plans to bring key commercial leaders on board in the first quarter of 2027.
Business Segments and Product Lines:
- Oxylanthanum Carbonate (OLC): The NDA resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from a new Drug Product (DP) manufacturing vendor, which received a "No Action Indicated" status during an FDA inspection in March 2024. The original DP vendor was recently inspected by the FDA; the company plans to align with the FDA on whether a compliance determination for that facility could shorten the review timeline.
- UNI-494: This investigational treatment for acute kidney injury has received orphan drug designation (ODD) from the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
- Commercial Readiness: The company is in active discussions with dialysis organizations and is optimizing patient access across all reimbursement settings through its UniSource™ support hub.
Market and Competitive Landscape:
- On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) issued the calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule, establishing permanent phosphate binder funding within the dialysis bundled payment via a $12.85 per-treatment addition to the base rate effective January 1, 2027.
- CMS finalized a hyperphosphatemia clinical quality measure beginning with payment year 2029, based on 2027 performance, reinforcing the importance of sustained phosphorus control.
- Unicycive believes these CMS changes create favorable commercial launch conditions for OLC, subject to FDA approval and CMS confirmation of Transitional Drug Add-on Payment Adjustment (TDAPA) eligibility.
- Subject to FDA approval and CMS confirmation, OLC could potentially qualify for two years of separate reimbursement at 100% of average sales price while dialysis providers receive the new funding for binders embedded in the base rate.
- Unicycive believes OLC meets criteria for TDAPA eligibility upon FDA approval, citing its classification as a Type 2 NDA under the FDA's Manual of Policies and Procedures 5018.2 because it contains a new active ingredient (oxylanthanum carbonate) despite containing a previously approved active moiety (lanthanum).
Risks and Challenges:
- The company does not know whether the FDA will conduct a pre-approval inspection of the new DP vendor.
- The determination of OLC's NDA classification rests solely with the FDA and remains subject to the agency's determination at the time of approval.
- Forward-looking statements note risks including clinical trial uncertainties, potential suspension or discontinuation of trials due to safety risks, dependence on third-party manufacturers, business interruptions, dependence on key personnel, substantial competition, patent protection uncertainties, and the risk of failure to obtain FDA clearances or approvals.
Management Commentary and Tone:
- Shalabh Gupta, M.D., Chief Executive Officer, stated that the FDA's acceptance of the NDA resubmission marks an important step toward bringing the treatment to patients and emphasized the focus on advancing launch preparations in parallel with the FDA review.
- The tone reflects confidence in the regulatory pathway and commercial potential, citing favorable CMS payment changes and the company's readiness to hire a sales force and engage with commercial leaders upon approval.
Other Key Points:
- The original Complete Response Letter (CRL) received in June 2026 did not raise concerns regarding clinical efficacy or safety data or request additional data from the company; the deficiencies cited were related to the original Drug Product vendor.
- OLC is a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
- The company is a biotechnology firm developing therapies for kidney diseases, with OLC as its lead investigational treatment.
- Company
- UNICYCIVE THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology